➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Moodys
McKesson
Dow
Express Scripts

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Fluoropyrimidine


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Fluoropyrimidine?

Fluoropyrimidine is an investigational drug.

There have been 232 clinical trials for Fluoropyrimidine. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2016.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Stomach Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Hoffmann-La Roche, and Eli Lilly and Company.

There are four hundred and eighty-four US patents protecting this investigational drug and five international patents.

Recent Clinical Trials for Fluoropyrimidine
TitleSponsorPhase
Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal CancerUNICANCERPhase 2
A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.Qilu Pharmaceutical Co., Ltd.Phase 2/Phase 3
Neoadjuvant Therapy for Localized Rectal AdenocarcinomaUNC Lineberger Comprehensive Cancer CenterPhase 2

See all Fluoropyrimidine clinical trials

Clinical Trial Summary for Fluoropyrimidine

Top disease conditions for Fluoropyrimidine
Top clinical trial sponsors for Fluoropyrimidine

See all Fluoropyrimidine clinical trials

US Patents for Fluoropyrimidine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fluoropyrimidine   Start Trial Fibre-reactive 1:1 chromium complex azo or azomethine dyes having a bidentate chelating group and a monofunctional neutral ligand Ciba-Geigy Corporation (Ardsley, NY)   Start Trial
Fluoropyrimidine   Start Trial Reactive dyes containing the 2-(cyano, carbonamido, sulfo-, hydroxy- or sulfato-C.sub.2 -C.sub.5 -alkyleneamino)-6-sulfo- or 3,6-disulfo-8-hydroxynaphthyl-(1) coupling component Ciba-Geigy Corporation (Ardsley, NY)   Start Trial
Fluoropyrimidine   Start Trial Certain 2-pyridyl oxy-phenyl acrylates having fungicidal, insecticidal, nematocidal and plant growth regulating activity Imperial Chemical Industries PLC (London, GB2)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Baxter
Medtronic
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.